Bristol-Myers Squibb ( BMY) and Pfizer ( PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrialfibrillation and at least one risk factor for stroke.
Rivaroxaban is currently indicated in the US for stroke reduction in patients with atrialfibrillation, for the treatment and prevention of recurrence of deep venous thrombosis and pulmonary embolism, and for DVT prophylaxis after orthopedic surgery.